Presentation (CTI)

OBJECTIVES: The Mantara® PGx DNA Test provides personalized pharmacogenetic insights by analysing 12 genes, to optimize treatment effectiveness and reduce the risk of adverse drug reactions. The NHS over-40s Health Check, which is offered every five years to individuals aged 40 to 74, screens for risks related to cardiovascular health, diabetes, kidney function, and stroke. This program reaches approximately 1.1 million people each year and could serve as a potential opportunity for integrating the Mantara® PGx DNA Test. However, its cost-effectiveness in this context has not yet been evaluated.
METHODS: A targeted literature review was conducted to identify UK-based economic evaluations relevant to pharmacogenetics. Using a structured framework, a health economic model was constructed to assess the cost-effectiveness of implementing the Mantara® PGx DNA Test alongside the NHS over-40s Health Check. Sensitivity and scenario analyses were performed to explore uncertainty across key model parameters.
RESULTS: Five cost-effectiveness studies from the UK were included, covering four drug-indication pairings. Additional clinical data on alternative treatment strategies and adverse reactions, particularly for cardiovascular agents such as statins and anti-arrhythmics, were used to assess the value of these gene-drug interactions within the Mantara® PGx DNA Test. In the base-case analysis, a targeted panel of five gene-indication pairings produced incremental health gains below the commonly accepted threshold of £20,000 per QALY, indicating favorable cost-effectiveness.
CONCLUSIONS: Embedding personalised pharmacogenetic profiling within the NHS over-40s Health Check may offer cost-effective benefits. As some alleles confer actionability only upon diagnosis, future implementation must consider how such latent information alters long-term practice. Strengthening the evidence base is essential to inform NHS-wide change.